ROS1 and non-small cell lung carcinoma: While 71% of patients with NSCLC have actionable alterations (e.g., EGFR, ALK, BRAF, ERBB2, MET, ROS1, RET, and KRAS), some have non-actionable mutations with prognostic and/or predictive implications (e.g., PIK3CA, STK11, and TP53) [20,21,22].